CML HealthCare Enters into an Arrangement Agreement with LifeLabs Medical Laboratory Services to Acquire the Outstanding Shares of CML

CML HealthCare Inc. (CLC) (the "Company" or "CML"), announced today that it has entered into an Arrangement Agreement (the "Arrangement") with a newly formed Ontario corporation established by LifeLabs Inc., the general partner of LifeLabs Medical Laboratory Services ("LifeLabs"). LifeLabs is indirectly owned by OMERS Administration Corporation ("OMERS"), whose interest is managed by Borealis Infrastructure ("Borealis"). The Arrangement provides for the acquisition of all issued and outstanding shares of CML for $10.75 per share in cash by way of a Plan of Arrangement under the Business Corporations Act (Ontario). The total transaction, including the assumption of CML's outstanding debt of $255 million at March 31, 2013, is valued at approximately $1.22 billion. 

Published: 25 June 2013
Written by Editor
TSX   Healthcare   M & A   Up on News   Interesting News  
Read more: CML HealthCare Inc ( CLC )

CombiMatrix Granted Conditional Approval From New York State Department of Health to Market Prenatal Miscarriage Analysis Test

Opens Large New Market for Leading Growth Product

CombiMatrix Corporation (CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its chromosomal microarray analysis (CMA) test for miscarriage analysis has received conditional approval from the New York State's Department of Health for testing on patient samples from the state. With nearly 20 million people, New York is the third most populated state in the nation, behind only California and Texas.

Published: 25 June 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: CombiMatrix Corporation ( CBMX )

Rosetta Genomics Executes Credentialing Agreement with Three Rivers Provider Network

Preferred Provider Organization network has more than 10 million covered lives; one-in-five Americans now covered for the Rosetta Cancer Origin Test™

Rosetta Genomics Ltd. (ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed a credentialing agreement with Three Rivers Provider Network, Inc. (TRPN) of Chula Vista, Calif., for the Rosetta Cancer Origin Test.  TRPN is one of the largest supplemental Preferred Provider Organizations (PPO) in the U.S., providing healthcare benefits to more than 10 million members nationwide.

Published: 07 June 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Rosetta Genomics Ltd ( ROSG )

BG Medicine Announces Late-Breaker Oral Presentation of New Data on the BGM Galectin-3(R) Test in Heart Failure

European Society of Cardiology Heart Failure Congress Features 15 Presentations and Two Symposia on Galectin-3

BG Medicine, Inc. (Nasdaq:BGMD) today announced the presentation of new clinical research data on the BGM Galectin-3® test in heart disease at the 2013 European Society of Cardiology Heart Failure Congress (ESC-HF) in Lisbon, Portugal. Among the highlights was a late-breaking oral presentation of results from the Aldo-DHF Biomarker Substudy which demonstrated the usefulness of galectin-3 testing for assessing functional capacity and clinical prognosis in patients diagnosed with a form of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF).i Heart Failure with Preserved Ejection Fraction is the fastest growing type of clinical heart failure in the United States and Europe, disproportionately affecting women and accounting for one-third to one-half of all hospital admissions for heart failure.ii

Published: 28 May 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: BG Medicine Inc ( BGMD )

Nordion Enters into Agreement to Divest Targeted Therapies Business to BTG plc

Nordion Inc. (NDN.TO) (NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced that it has entered into an agreement to divest its Targeted Therapies business to BTG plc (BTG.L) (“BTG”), an international specialist healthcare company based in London, United Kingdom, for a cash purchase price of US$200 million. Net of cash taxes and transaction costs, Nordion expects to realize approximately US$185 million on closing. The transaction is anticipated to be completed by the end of June 2013.

Nordion manufactures and commercializes TheraSphere®, a targeted liver cancer therapy, the sole product in its Targeted Therapies business. Under the terms of the transaction agreements, BTG is expected to acquire TheraSphere and Nordion has agreed to continue manufacturing TheraSphere under a Manufacturing and Support Agreement with a contract term of three years, plus a two-year extension at BTG’s option. Approximately 40 Nordion employees are expected to join BTG following the completion of this transaction, which is subject to customary closing conditions and approval by BTG shareholders.

Published: 23 May 2013
Written by Editor
TSX   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Nordion Inc ( NDN )
  1. Genomic Health Inc ( GHDX )
  2. Genetic Technologies Limited ( GENE )
  3. CombiMatrix Corporation ( CBMX )
  4. GenMark Diagnostics Inc ( GNMK )
  5. Atossa Genetics Inc ( ATOS )